ArticleNature communications2017
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- The paradox of nuclear miRNAs: Mechanisms, therapeutic potential, and future directions.Non-coding RNA research · 2026Review
- CDH1 reduces endothelial cell permeability by enhancing CDH5 membrane expression under chronic intermittent hypoxia.European journal of medical research · 2025Article
- SUV39H1 regulates progression of pediatric diffuse high-grade gliomas through modulation of β-catenin/TCF4 levels.Journal of molecular medicine (Berlin, Germany) · 2025Article
- CDH1 genetic variants and its aberrant expression are the risk factors for colorectal cancer metastasis.BMC gastroenterology · 2025Article
- Review
- Role ofFrontiers in oncology · 2025Article
- Liver X Receptors Enhance Epithelial to Mesenchymal Transition in Metastatic Prostate Cancer Cells.Cancers · 2024Article
- Nuclear miRNAs: Gene Regulation Activities.International journal of molecular sciences · 2024Review
- Review
- The Wnt-pathway corepressor TLE3 interacts with the histone methyltransferase KMT1A to inhibit differentiation in Rhabdomyosarcoma.Oncogene · 2024Article
- Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023Review
- A functional SNP regulates E-cadherin expression by dynamically remodeling the 3D structure of a promoter-associated non-coding RNA transcript.Nucleic acids research · 2022Article
- Targeting non-coding RNAs to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2022Review
- Article
- Loss of lncRNA SNHG8 promotes epithelial-mesenchymal transition by destabilizing CDH1 mRNA.Science China. Life sciences · 2021Article
- Aberration-corrected ultrafine analysis of miRNA reads at single-base resolution: a k-mer lattice approach.Nucleic acids research · 2021Article
- The Importance of Epigenetics in Diagnostics and Treatment of Major Depressive Disorder.Journal of personalized medicine · 2021Review
- MicroRNAs: immune modulators in cancer immunotherapy.Immunotherapy advances · 2021Review
- Emerging Contribution of PancRNAs in Cancer.Cancers · 2020Review
- Dissecting the transcriptional regulatory networks of promoter-associated noncoding RNAs in development and cancer.Journal of experimental & clinical cancer research : CR · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 4 countries.
Funding
Abstract
Long noncoding RNAs are emerging players in the epigenetic machinery with key roles in development and diseases. Here we uncover a complex network comprising a promoter-associated noncoding RNA (paRNA), microRNA and epigenetic regulators that controls transcription of the tumour suppressor E-cadherin in epithelial cancers. E-cadherin silencing relies on the formation of a complex between the paRNA and microRNA-guided Argonaute 1 that, together, recruit SUV39H1 and induce repressive chromatin modifications in the gene promoter. A single nucleotide polymorphism (rs16260) linked to increased cancer risk alters the secondary structure of the paRNA, with the risk allele facilitating the assembly of the microRNA-guided Argonaute 1 complex and gene silencing. Collectively, these data demonstrate the role of a paRNA in E-cadherin regulation and the impact of a noncoding genetic variant on its function. Deregulation of paRNA-based epigenetic networks may contribute to cancer and other diseases making them promising targets for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.